The REALITY Trial is a prospective, randomized study involving 1,386 patients at 90 hospitals centers in Europe, Latin America and Asia.

In the REALITY trial, patients were included if they had up to two de novo ( new ) lesions with a primary lesion of at least 15 mm in length in small vessels ( 2.25 to 3.0 mm in diameter ).

Cypher and Taxus are drug-eluting stents.

The study demonstrated that both products were efficacious, at comparable rates, in preventing in-segment binary restenosis ( re-clogging ), which was the primary endpoint of the study.

Cypher, Sirolimus-eluting coronary stent, was associated with development of significantly fewer blood clots at the stent site ( stent thrombosis ) than Taxus, Paclitaxel-eluting coronary stent (p=0.020).

The incidence of stent thrombosis was 78 percent lower with the Cypher stent than with the Taxus stent.

Source : American College of Cardiology Annual Scientific Session, 2005

XagenaMedicine2005